...A. Wauquier; A. Declerck Fifteen general practitioners treated 21 newly diagnosed insomniac patients with benzodiazepines. In 15 cases, a short-acting benzodiazepine was prescribed without regard to the type, severity, duration and probable cause of insomnia. Sleep-wake ambulatory recordings were...

..., that the statistically significant effects were weak and in part could be due to an incidental change in the placebo group. As none of the other measures, including subjective sleep quality, showed any change, it was concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major...

..., on clinical symptomatology, sleep and anxiety of 45 patients with insomnia based on a mild to moderate generalized anxiety disorder (GAD) (ICD-9 code: 307.42-1, 300,0; ASDC-APSS-Code: A.2.a), we compared, in a first step at baseline, drug-free polysomnographic and psychometric data of 22 patients recorded...

...François Charon; Michèle Dramaix; Julien Mendlewicz Clinical data about insomnia and its treatment were collected in a sample of 1,761 patients who had consulted general practitioners for insomnia. In this sample, we found an incidence of 53% of patients presenting some psychiatric symptoms. We...

... with an intensity of 45-65 dB(A) induced sleep disturbances characterized by an increase in intermittent wakefulness and stage 1 and the number of nocturnal awakenings as well as by a decrease of spindle and REM sleep stages. Subjectively, a decrease of deep sleep and increase of light sleep and middle insomnia...

... vigilances’. Whereas the somnogenic actions of DSIP appear promising for treating insomnia, other therapeutic perspectives in the field of psychiatry have to be explored. 19 2 2008 © 1983 S. Karger AG, Basel 1983 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

...Barbara Knab; Pola Engel-Sittenfeld Insomnia is a syndrome composed of symptoms of disturbed sleep, decrement of day-time performance and depressed mood to various degrees and in various combinations. This article roughly describes the methods of measuring the different facets of insomnia. A major...

..., anxiety and insomnia. On the occasion of the introduction of a controlled-release (CR) formulation (Trittico ® 150 mg retard, marketed in Austria by CSC Pharmaceuticals Handels GmbH, Vienna, Austria) in Austria in July 2000, a multi-center, open, clinical post-marketing study on the therapeutic effects...

...D. Schneider-Helmert; I. Whitehouse; A. Kumar; C. Lijzenga A considerable proportion of chronic non-organic pain patients suffer from insomnia, and alpha sleep has been suggested to be specifically associated with fibromyalgia. However, the clinical significance of those symptoms is not clear...